Generic olanzapine: Health authority opportunity or nightmare?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 6, 2008, Pages 549-555

  Araszkiewicz, A Aleksander ^a   Szabert, Katarzyna ^a   Godman, Brian ^b,c   Wladysiuk, Magdalena ^d   Barbui, Corrado ^e   Haycox, Alan ^c  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d HTA CONSULTING   (Poland)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

Atypicals; Drug costs; Generic drugs; Olanzapine; Relapses; Schizophrenia

Indexed keywords

GENERIC DRUG; OLANZAPINE; UNCLASSIFIED DRUG; ZAPONEX;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; FOLLOW UP; HUMAN; MONOTHERAPY; PATIENT COMPLIANCE; POLAND; PRESCRIPTION; RECURRENCE RISK; SCHIZOPHRENIA; UNITED STATES;

EID: 68649101585     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.6.549     Document Type: Article

References (39)

1. Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy, a comparison in seven European countries. Health Policy 85, 305-813 (2008).
2. Cook J, Vernon J, Mannin R. Pharmaceuical risk-sharing agreements. Pharmacoeconomics 26(7), 551-556 (2008).
3. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson L. Enhancing the rational use of new medicines across European healthcare systems - Editorial. Eur. J. Clin. Pharmacol. 64(12), 1137-1138 (2008).
4. Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med. 359(4), 333-335 (2008).
5. Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7), 537-550 (2008).
6. Kusnik-Joinville O, Weill A, Salanave B et al. Prevalence and treatment of diabetes in France, trends between 2000 and 2005. Diabetes Metab. 34, 266-272 (2008).
7. Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res. 8 (4), 357-371(2008).
8. Godman B. Performance measurement and investment decision making - rhetoric versus reality. In: Managed Care. Preuss KJ, Räbiger R, Sommer JH (Eds). Schattauer GmbH, Germany, 201-211 (2002).
9. Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin. 23(11), 2647-2654 (2007).
10. Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev. Clin. Pharmacol. 1(4), 497-503 (2008).
11. Kanavos P. Generic policies, rhetoric vs. reality. Euro Observer 10 (2),1-6 (2008).
12. Duerden M. Making sense of drug pricing. Prescriber supplement (2006). John Wiley & Sons Ltd, Chichester, UK.
13. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it, Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91-98 (2008).
14. Chaplin S, Duerdin M. When brands are best - brand vs. generic prescribing. Prescriber Guide Supplement (2006). Printed and published by John Wiley Sons Ltd, Chichester, UK.
15. Yu B, Yuri SC, Maguire A. Is generic fluoxetine effective? J. Affect. Disord. 81, 185-186 (2004).
16. Van Ameringen M, Mancini C, Patterson B, Bennett M. Symptom relapse following switch from Celexa to generic citalopram, an anxiety disorders case series. J. Psychopharmacol. 21(5), 472-476 (2007).
17. Vergouwen A, Bakker A. Adverse effects after switching to a different generic form of paroxetine, paroxetine mesylate instead of paroxetine HCI hemihydrate. Ned. Tijdschr. Geneskd 146(17), 811-12 (2002).
18. Mofsen R, Batter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin. Ther. 23, 1720-1731 (2001).
19. Alvarez CA, Mascarenas C, Timmerman I. Increasing psychosis in a patient switched from Clozaril to generic clozapine. Am. J. Psychiatry 163 (4), 746 (2006).
20. Whisky E, Taylor D. Generic clozapine, opportunity or threat? Pharmaceutical J. 273, 112 (2004).
21. Nuss P, Taylor D, De Hert M, Hummer M. The generic alternative in schizophrenia, opportunity or threat? CNS Drugs 18 (12), 769-775 (2004)
22. Healy DJ, Taylor S, Goldman M, Barry K, Blow F, Milner KK. Clinical equivalence of generic clozapine. Community Ment. Health J. 41(4), 393-398 (2005).
23. Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM. Evaluation of an interchangeability switch in patients treated with clozapine, a retrospective review. J. Clin. Psychiatry 67(7), 1047-1054 (2006).
24. Paton C. Generic clozapine, outcomes after switching. Br. J. Psychiatry 89, 184-185 (2006)
25. Bazire S, Burton V. Generic clozapine in schizophrenia, what is all the fuss about? Pharmaceutical J. 173, 720-721 (2004).
26. Andretta M, Ciuna A, Corbari L et al. Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc. Psychiatry Psychiatr. Epidemiol. 40, 72-77 (2005).
27. Knapp M, Kanavos P, King D, Yesudian HM. Economic issues in access to medications, schizophrenia treatment in England. Int. J. Law Psychiatry 28, 514-531 (2005).
28. Mirandola M, Andretta M, Corbari L et al. Prevalence, incidence and persistence of antipsychtic drug prescribing in the Italian general population, retrospective database analysis, 1999-2002. Pharmacoepidemiol. Drug Saf. 15, 412-420 (2006).
29. Rosenheck R, Swartz M, McEvoy J et al. Second-generation antispychotics, reviewing the cost-effectiveness component of the CATIE trial. Expert Rev. Pharmacoeconomics Outcomes Res. 7(2), 103-111 (2007).
30. Liu GG, Sun SX, Christensen DB, Luo X. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann. Pharmacother. 38, 134-141 (2004).
31. Barbui C, Lintas C, Percudani M. Head-to-head comparison of the cost of atypical antipsychotics - a systematic review. CNS Drugs 19 (1), 935-950 (2005).
32. Paris V. Pharmaceutical regulation in France 1980 - 2003. Int. J. Health, Plann. Manage. 20, 307-328 (2005).
33. Garattini L, Ghislandi S. Off-patent drugs in Italy, a short sighted view? Eur. J. Health Econ. 7, 79-83 (2006).
34. Seeley E, Kanavos P. Generic medicines from a societal perspective, savings for healthcare systems? Eurohealth 14(2), 18-22 (2008).
35. Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France, is there room for further efficiency savings. Curr. Med. Res. Opin. 23, 2467-2476 (2007).
36. Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr. Med. Res. Opin. 23(1), 105-116 (2007).
37. Frank RG. The ongoing regulation of generic drugs. NEJM 357(20), 1993-1996 (2007).
38. van Os S, Relleke M, Piniella PM. Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets. Int. J. Clin. Pharmacol. Ther. 45(5), 293-299 (2007).
39. Jack A. Balancing Big Pharma's books. BMJ 336, 418-419 (2008).